#weightlossdrug #semaglutide #fattyliverdisease
A new phase 3 clinical trial published this week in The New England Journal of Medicine concludes that semaglutide, a widely used diabetes medication, can halt and even reverse metabolic dysfunction-associated steatohepatitis (MASH), a severe and increasingly common liver disease. The international study, led by Dr. Arun Sanyal of Virginia Commonwealth University and Dr. Philip Newsome of King’s College London, offers strong evidence that semaglutide not only improves liver health but also addresses the underlying metabolic dysfunction driving the disease.
MASH, previously known as NASH, is linked to obesity, type 2 diabetes, and hypertension, and can progress to cirrhosis or liver failure. It currently affects millions globally, with fatty liver disease impacting about 36% of the global population as of 2019. Despite its prevalence, only one FDA-approved treatment exists for the broader spectrum of fatty liver disease, highlighting the urgent need for new therapeutic options.
The trial involved patients across 37 countries and assessed the effects of semaglutide, a GLP-1 receptor agonist, on individuals diagnosed with MASH. Participants received semaglutide over a prolonged period, and researchers tracked changes in liver histology, biomarkers, body weight, and other metabolic indicators. Results showed that semaglutide led to significant reductions in liver fat, inflammation, and fibrosis, with many patients achieving resolution of MASH without worsening fibrosis. Additionally, the drug contributed to notable weight loss and improvements in cardiovascular and metabolic health.
Check full updates on Medical Dialogues
Also check out –
Medical Dialogues Academy, a renowned academic wing of Medical Dialogues – India’s premier health and news online portal, proudly presents this comprehensive course tailored for healthcare professionals eager to delve into the realm of medical journalism.
🔗 Enroll Today:
📚 Explore More With Us:
📌 Medical Content Writing:
📌 Certificate Course in Pharmaceutical Medico-Marketing:
Join us on this enlightening journey and become a part of a community pushing the boundaries of healthcare communication and reporting.
Get the latest medical and health news at medicaldialogues.in
Follow us on
Twitter:
Facebook:
Instagram:
LinkedIn:
Website:
source
